Edwards Lifesciences Corporation, the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Steven R. Loranger has been appointed to its board of directors. Loranger was most recently chief executive officer and president of leading global water technology company Xylem Inc., following his service as chairman, president and chief executive officer of ITT Corporation for seven years.
Prior to joining ITT, Loranger served as executive vice president and chief operating officer of Textron, Inc., and held executive positions at Honeywell International Inc. and its predecessor company, AlliedSignal, Inc.
“We are excited to welcome Steve to our board of directors, which will benefit from his decades of experience leading large, innovation-focused corporations,” said Michael A. Mussallem, Edwards’ chairman and CEO. “We look forward to his insights and global experience gained from service in a variety of highly regulated, high-tech industries with significant focus on quality.”
Currently, Loranger serves on the boards of directors of Xylem, Inc., the Smithsonian National Air and Space Museum and the Congressional Medal of Honor Foundation. He also served on the board of FedEx Corporation from 2006 to 2014.
A former U.S. Navy lieutenant, Loranger holds bachelor’s and master’s degrees from the University of Colorado.
Source: Edwards Lifesciences
Big Pharma has long seen the potential for AI and machine learning to accelerate drug development. But Novo Nordisk is going a step further by channeling $200 million toward the creation of a computer that will outrun anything in existence.
Current methods for diagnosing Alzheimer’s disease rely on a complex combination of self- and caregiver-reported symptoms, a physical examination and either a PET scan or a spinal tap to look for evidence of amyloid plaque build-ups in the brain. But a new artificial intelligence-based method may make the diagnostic process a much more objective one.
There is lots of talk about diversity and inclusion in business, including in pharma and medtech. A new report by the Open Political Economy Network (OPEN), a think tank focusing on migration and diversity, released its “Minority Businesses Matter: Europe” report highlighting the successes and challenges of ethnic minority-owned businesses in Europe.
